Abstract
Pediatric antiretroviral treatment programs have been rolled out in resource limited settings, providing lifesaving treatment to approximately 300,000 HIV-infected children. The standard first-line antiretroviral regimen is a nonnucleoside reverse transcriptase plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). A meta-analysis showed that 70% of children achieved virologic suppression after 12 months of first line therapy. This article presents the challenges in diagnosis of treatment failure in resource limited settings and reviews the current guidelines for management of HIV-infected children with second-line antiretroviral therapy. The details of antiretroviral drugs recommended for second line regimens are summarized. The current standard second-line regimen is a boostedprotease inhibitor-based regimen plus recycling NRTIs. The potential role of new ARV drug classes for second-line regimen is addressed.
Keywords: Pediatric HIV, antiretroviral therapy, resource limited settings
Current Pediatric Reviews
Title: Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings
Volume: 7 Issue: 3
Author(s): Linda Aurpibul and Thanyawee Puthanakit
Affiliation:
Keywords: Pediatric HIV, antiretroviral therapy, resource limited settings
Abstract: Pediatric antiretroviral treatment programs have been rolled out in resource limited settings, providing lifesaving treatment to approximately 300,000 HIV-infected children. The standard first-line antiretroviral regimen is a nonnucleoside reverse transcriptase plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). A meta-analysis showed that 70% of children achieved virologic suppression after 12 months of first line therapy. This article presents the challenges in diagnosis of treatment failure in resource limited settings and reviews the current guidelines for management of HIV-infected children with second-line antiretroviral therapy. The details of antiretroviral drugs recommended for second line regimens are summarized. The current standard second-line regimen is a boostedprotease inhibitor-based regimen plus recycling NRTIs. The potential role of new ARV drug classes for second-line regimen is addressed.
Export Options
About this article
Cite this article as:
Aurpibul Linda and Puthanakit Thanyawee, Second-Line Antiretroviral Therapy for HIV-Infected Children in Resource Limited Settings, Current Pediatric Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339611796548375
DOI https://dx.doi.org/10.2174/157339611796548375 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Metal Based Agents with Potential for Therapeutic and Diagnostic Applications (Guest Editors: Shigenobu Yano & Michael Gottschaldt)]
Current Topics in Medicinal Chemistry Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Serum Adiponectin Levels in Patients with Familial Mediterranean Fever
Protein & Peptide Letters Takotsubo Cardiomyopathy
Current Pharmaceutical Design The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Prevention of Neointimal Hyperplasia by Local Application of Lentiviral Vectors Encoding Pin1 shRNA in Pluronic F127
Current Gene Therapy Neuro-endocrine Markers in Neoplasms. Diagnostic Interest and Future Prospects
Current Proteomics Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review
Current Genomics Common Structural Stability Properties of 4-Helical Bundle Cytokines: Possible Physiological and Pharmaceutical Consequences
Current Pharmaceutical Design Prevention and Treatment of Cardiovascular Disease in Adolescents and Adults through the Transcendental Meditation® Program: A Research Review Update
Current Hypertension Reviews Nanoparticles as Novel Carrier for Brain Delivery: A Review
Current Pharmaceutical Design Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine The Possible Hypoglycemic Mechanisms of Echinochrome
Current Diabetes Reviews Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry Pharmacogenetics of Drug Transporters
Current Pharmaceutical Design Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Letters in Organic Chemistry Natural Products Modulating Autophagy Pathway Against the Pathogenesis of Diabetes Mellitus
Current Drug Targets Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome
Current Clinical Pharmacology Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Biological Predictors of Aging and Potential of FTIR to Study Age-related Diseases and Aging Metabolic Fingerprint
Current Metabolomics